Bevacizumab (anti-VEGF)

Catalog No.A2006 Synonyms: rhuMab VEGF, Avastin

For research use only.
Not for use in humans.

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Selleck's Bevacizumab (anti-VEGF) has been cited by 20 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Targets

VEGFR2 ^[4]

VEGF-A ^[4]

VEGF ^[1]

In vitro

Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.^[1]

In vivo

The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.^[2]

Protocol (from reference)

Cell Research:	Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.
Animal Research:	Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model Dosages: 2 mg/kg Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/

Cell Research:

Matrigel gels were created using low GF Matrigel (protein concentration > 9.5 mg/ml) in a 48-well plate. It was gelled at 37 ℃ overnight and then rinsed twice with PBS. endothelial cells (ECs) were added in 250 μl endothelial basal medium with no supplement and allowed to adhere for 1 hour. An additional 250 μl of 48 h conditioned medium from unaffected or affected fibroblasts or nonconditioned medium with or without 20 ng/ml VEGF and with or without 250 μl/ml bevacizumab in 5% FBS + 1% penicillin/streptomycin in DMEM was added, and ECs were incubated for 14 h before being fixed and stained for CD31. ECs network formation was also tracked by live-cell imaging at 2, 4, 8, 16, and 24 h.

Animal Research:

Animal Models: Male C57BL/6J mice of CCl4-induced fibrosis model
Dosages: 2 mg/kg
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/34940991/

References	[1] Hurley-Novatny AC, et al. J Invest Dermatol. 2022 Feb 19:S0022-202X(22)00125-7. [2] Lin Y, et al. Hepatology. 2021 Dec 23.

References

Product Details

CAS No.	216974-75-3
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	CHO cells
Storage	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.